Disclosures: Dr. Borgström is inventor on a patent in relation to this work and is also CEO of PellFiCure Pharmaceuticals, Inc. Dr. Baron is a consultant for PellFiCure Pharmaceuticals, Inc. Drs. P. Abedinpour, A. Chrastina, and J. Welsh declare no conflict of interest.
Article first published online: 19 SEP 2012
Copyright © 2012 Wiley Periodicals, Inc.
Volume 73, Issue 5, pages 489–499, April 2013
How to Cite
Abedinpour, P., Baron, V. T., Chrastina, A., Welsh, J. and Borgström, P. (2013), The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate, 73: 489–499. doi: 10.1002/pros.22585
Parisa Abedinpour and Véronique T. Baron contributed equally to this work.
- Issue published online: 14 MAR 2013
- Article first published online: 19 SEP 2012
- Manuscript Accepted: 21 AUG 2012
- Manuscript Received: 26 JUL 2012
- This work was supported by DOD-OCRP. Grant Number: W81XWH-09-1-0280
- PellFiCure Pharmaceuticals, Inc. Grant Number: PPI001
Additional Supporting Information may be found in the online version of this article.
|pros_22585_sm_SupplFig1.tif||274K||Supplementary Figure 1|
|pros_22585_sm_SupplFig2.tif||71K||Supplementary Figure 2|
|pros_22585_sm_SupplFig3.tif||63K||Supplementary Figure 3|
|pros_22585_sm_SupplFig4.tif||53K||Supplementary Figure 4|
|pros_22585_sm_SupplFig5.tif||322K||Supplementary Figure 5|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.